How blocking Raf activates the MAPK pathway

Pigment Cell and Melanoma Research

Volumn 23, Issue 2, 2010, Pages 187-189

  McCormick, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLX 4032; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAF PROTEIN INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER RESISTANCE; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; FEEDBACK SYSTEM; GENE FREQUENCY; GENE MUTATION; HUMAN; KERATOACANTHOMA; MEDIATOR; MELANOMA; MELANOMA CELL; NOTE; PHARMACOLOGICAL PARAMETERS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949346829     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00680.x     Document Type: Note

References (10)

1. Arnault, J.P., Wechsler, J., Escudier, B. et al. (2009). Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, 59-61.
2. Dougherty, M.K., Müller, J., Ritt, D.A., Zhou, M., Zhou, X.Z., Copeland, T.D., Conrads, T.P., Veenstra, T.D., Lu, K.P., and Morrison, D.K. (2005). Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224.
3. Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P. (2009). Phase I study of PLX4032: proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27, 15s.
4. Friday, B.B., Yu, C., Dy, G.K., Smith, P.D., Wang, L., Thibodeau, S.N., and Adjei, A.A. (2008). BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68, 6145-6153.
5. Garnett, M.J., Rana, S., Paterson, H., Barford, D., and Marais, R. (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969.
6. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
7. Hall-Jackson, C.A., Eyers, P.A., Cohen, P., Goedert, M., Boyle, F.T., Hewitt, N., Plant, H., and Hedge, P. (1999). Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568.
8. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
9. Karreth, F.A., DeNicola, G.M., Winter, S.P., and Tuveson, D.A. (2009). C-Raf inhibits MAPK activation and transformation by B-Raf (V600E). Mol. Cell 36, 477-486.
10. Mirzoeva, O.K., Das, D., Heiser, L.M. et al. (2009). Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565-572.